Log In
BCIQ
Print this Print this
 

AMG 181

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHuman mAb to alpha4/beta7 that blocks binding of mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1)
Molecular Target Mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$50.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/02/2012

Undisclosed

$50.0M

0

Get a free BioCentury trial today